

Primary outcome analysis (ITT)

Descriptive summaries of endpoints

Table 1: Descriptive summary of Total Hip BMD over time

Characteristic	Total Hip BMD (g/cm ²)		P-value	*Difference in % change from baseline	
	Alendronate (N = 24)	Placebo (N = 26)		Median difference (95% CI)	P-value
Week 0					
N	24	23			
Median (IQR)	1.082 (0.982, 1.278)	1.040 (0.911, 1.152)	0.23		
Mean (SD)	1.104 (0.153)	1.056 (0.193)			
Week 14					
N	17	25			
Median (IQR)	1.063 (1.013, 1.315)	1.045 (0.919, 1.137)	0.15		
Mean (SD)	1.126 (0.158)	1.082 (0.220)			
%Change (median, IQR)	+1.88 (-0.70; 2.81)	-0.65 (-2.65, 1.13)		+2.04 (0.17; 4.22)	0.036
Week 26					
N	18	23			
Median (IQR)	1.107 (0.985, 1.292)	1.028 (0.926, 1.126)	0.15		
Mean (SD)	1.129 (0.155)	1.067 (0.172)			
%Change (median, IQR)	+1.05 (-2.05, 2.23)	-2.03 (-2.97, 0.63)		+1.97 (-1.06; 3.87)	0.22
Week 50					
N	22	20			
Median (IQR)	1.052 (0.958, 1.158)	1.043 (0.963, 1.094)	0.67		
Mean (SD)	1.080 (0.149)	1.056 (0.145)			
%Change (median, IQR)	+0.50 (-3.10, 1.80)	-2.70 (-4.30, -2.05)		+3.12 (0.53; 5.05)	0.02

IQR-Interquartile range, SD-standard deviation, BMD-Bone mineral density

P-values for comparing the two treatment groups were calculated from the 2-sided Wilcoxon rank sum

Median difference and 95% CI based Hodges-Lehmann estimate